CADILAHC Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > cadilahc

Technical Analysis

Technical Strength: 5.5 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 55.1. According to RSI analysis, cadilahc just got above it's resistance level and showing good signal. 9.0 CADILAHC RSI Chart
MACD (?) MACD: -0.657 and Signal Line: -0.369. According to MACD analysis, cadilahc is technically weak. 2.0 CADILAHC MACD Chart
Simple Moving Average (?) Price just got above it's 50-day simple moving average which is a positive signal. Price just got above it's 20-day simple moving average which is a positive signal. According to simple moving average analysis, cadilahc is facing resistance from it's 200-day simple moving average at 269.7905 and support level is at 242. 8.0 CADILAHC Simple Moving Average Chart
Exponential Moving Average (?) 20-day exponential moving average just got above it's 50-day exponential moving average which is a positive signal. Price just got above it's 50-day exponential moving average which is a positive signal. Price just got above it's 20-day exponential moving average which is a positive signal. According to exponential moving average analysis, cadilahc is facing resistance from it's 200-day exponential moving average at 268.5876 and support level is at 239. 8.0 CADILAHC Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.566. 5.0 CADILAHC Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above 50% and below 61.2% level. Support is at 240.85 and 235.9294. Resistance is at 245.7706. 3.5 CADILAHC Fibonacci Retracement Chart
Average True Range (?) ATR: 8.91 NA CADILAHC Average True Range Chart
Average Directional Index (?) ADX is 18.3 which means CADILAHC is in a trading range and there is no trend. NA CADILAHC Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
November 19, 2019
Open Price 242.0
High Price 246.95
Low Price 239.25
Close Price 243.7
Absolute Change 2.2
Percentage Change 0.911%
Weekly Change 5.75%
Monthly Change 1.27%
Yearly Change -30.4%
52-week high 375.4
52-week low 206.5
Corporate Actions
ExDate Purpose
July 25, 2019 AGM/DIV-RS 3.50 PER SH
July 31, 2018 AGM/DIV-RS 3.50 PER SHARE
July 31, 2018 DIV-RS 3.50 PER SHARE
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.462
Confidence in Beta1.96%
Market Capital Rs. 4989.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 19 November 2019: Deliverable Quantity:7.23e+05 NA CADILAHC Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 19 November 2019: Daily Volatility:0.3859 NA CADILAHC Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 19 November 2019: PCR_OI:0.493 PCR:0.278 NA CADILAHC PCR Chart
Option Pain (?) 19 November 2019: Max Pain:240.0 NA CADILAHC Option Pain Chart
Premium (?) 19 November 2019 Premium: 0.3 Futures OI:8003200.0 NA CADILAHC Premium Chart
Option_MAX_OI (?) 19 November 2019: Price:243.7 Put with maximum OI:200.0 Call with maximum OI:245.0 NA CADILAHC Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
November 28, 2019 244.0 8003200.0 1377.0 1377.0 243.7
December 26, 2019 245.05 392000.0 82.0 82.0 243.7
January 30, 2020 245.0 19800.0 0.0 0.0 243.7

Announcements

June 28, 2019 Related Party Transactions Cadila Healthcare Limited has informed the Exchange regarding Half yearly disclosure of Related Party transactions under Reg 23(9) of SEBI (LODR), 2015.
April 26, 2018 CaPress Releaseadila Healthcare Limited has informed the Exchange regarding a press release dated April 25, 2018, titled "Zydus receives final approval from the USFDA for Methylprednisolone Tablets USP and Cinacalcet Hydrochloride Tablets".
See all Announcements

Board Meetings

Date Meeting Date Purpose
October 22, 2019 November 13, 2019 Financial Results To consider and approve the financial results for the period ended September 30, 2019
July 16, 2019 August 09, 2019 Financial Results To consider and approve the financial results for the period ended Jun 30, 2019
See all Board Meetings

CADILAHC is part of...

Index Weightage
CNXPHARMA NA

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play